TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study published in Nature Medicine links lower levels of the protective protein NRF2 in oligodendrocytes with abnormal myelin and faster cognitive decline. Experiments in mice support a possible biological role, but the findings do not show that NRF2-targeting drugs prevent age-related decline in people.
Researchers have linked dysfunction in oligodendrocytes—brain cells that maintain the insulating coating around nerve fibers—to faster cognitive decline in older people. The study, published in Nature Medicine, found that lower levels of the protective protein NRF2 in these cells were associated with abnormal myelin and nerve-fiber changes, while experiments in mice offered evidence that reducing NRF2 can cause similar damage.
The research team, led by scientists from the University of Edinburgh and the UK Dementia Research Institute, studied members of the Lothian Birth Cohort 1936, whose cognitive abilities have been tracked from childhood into later life. Of 1,091 people enrolled, 866 completed additional testing after age 70. Assessments between ages 70 and 82 measured memory, information-processing speed and spatial reasoning. Most participants experienced some decline, but its pace varied.
In brain tissue collected after death from a subset of participants, greater cognitive decline was associated with fewer large nerve fibers and an abnormal accumulation of myelin. Myelin normally insulates nerve fibers and helps signals travel efficiently. The researchers reported that the tissue changes were associated with the rate of decline, rather than a person’s cognitive test performance at a single age.
The team then examined oligodendrocytes, which make and maintain myelin. People with more severe decline had lower NRF2 levels in these cells. In mice, selectively reducing NRF2 in oligodendrocytes led to excessive myelin, loss of large nerve fibers and weaker improvements in cognitive performance as the animals aged. These animal experiments support a possible causal role for the pathway, but do not establish that the same intervention or its effects apply directly to people.
A New Target in Brain Aging
The findings challenge the simple view that cells responsible for supporting nerve fibers remain uniformly beneficial throughout life. They suggest that age-related changes in oligodendrocyte function may be part of the biological processes associated with declining memory and thinking skills, rather than myelin being only a passive marker of brain health.
The NRF2 pathway may offer a direction for treatment research because medicines that act on it are already used for other neurological conditions. The source report notes that a drug targeting NRF2 is prescribed for multiple sclerosis and that earlier studies found cognitive improvements in people with MS when NRF2 activity was increased. Those points do not establish that the drug would help people with age-related cognitive decline. Any potential benefit, suitable dose, safety and patient group would need to be tested directly.
Popular right now
Dyson Ball Animal 3 Upright Vacuum
Breville Bambino Espresso Machine, Brushed Stainless Steel (BES450BSS)
Vitamix 5200 Professional-Grade Blender, 64 oz. Container, Black
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Decline
The Lothian Birth Cohort offers an unusually long record of cognitive testing, allowing researchers to compare changes across decades rather than relying only on a snapshot taken in old age. For this study, investigators considered cognitive assessments from ages 70 to 82 and examined brain tissue from a subset of participants after death.
The human findings show an association between the pace of cognitive decline and features of myelin and nerve fibers. The mouse experiments added evidence that reducing NRF2 in oligodendrocytes can produce related changes in animals. Together, the two parts of the study connect a pattern seen in human tissue with a mechanism researchers could test experimentally, but they do not amount to a clinical trial of a treatment in older adults.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Treatment Benefits Remain Untested
The study does not show that an NRF2-targeting medicine can slow or prevent cognitive decline in older people. The human tissue analysis was observational, and the animal experiments cannot determine whether a drug would have the same effects in humans. The source material does not provide a clinical trial in older adults, a treatment schedule, or evidence about potential benefits and risks for this use.
It also remains unclear how oligodendrocyte changes relate to other causes of cognitive decline, and whether restoring NRF2 activity would reverse existing nerve-fiber or myelin damage. The human analysis involved tissue from only a subset of the cohort, so the findings need further testing in broader groups.
Testing the NRF2 Pathway
The next step is to establish whether medicines that affect NRF2 can safely improve or preserve cognitive function in people experiencing age-related decline. Researchers would need to test that question in clinical studies, while determining which patients might benefit and whether treatment changes myelin or nerve-fiber health. Until such evidence is available, the study identifies a potential research target, not a treatment recommendation.
Key Questions
What brain cells did the study examine?
It focused on oligodendrocytes, cells that produce and maintain myelin, the insulating coating around nerve fibers.
What did the researchers find in human brain tissue?
Among the examined participants, greater cognitive decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes. The findings show associations, not proof that these changes caused an individual’s decline.
Did the study test a treatment in older people?
No. The research included human cohort and tissue analyses and experiments in mice. It did not test an NRF2-targeting drug as a treatment for age-related cognitive decline in older adults.
Could an existing multiple sclerosis drug help prevent cognitive decline?
The report says a medicine targeting the NRF2 pathway is used for multiple sclerosis, but whether it helps people with age-related cognitive decline is unknown. That possibility would need to be assessed in clinical trials.
Source: rss
